Rhumbline Advisers Gritstone Bio, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.62 - $2.35 $63,388 - $240,264	-102,240 Reduced 80.24%	25,183 $15,000
Q1 2024 May 09, 2024	BUY	$1.96 - $2.9 $7,344 - $10,866	3,747 Added 3.03%	127,423 $327,000
Q4 2023 Feb 08, 2024	SELL	$1.28 - $2.85 $697 - $1,553	-545 Reduced 0.44%	123,676 $252,000
Q3 2023 Nov 09, 2023	SELL	$1.19 - $2.26 $6,940 - $13,180	-5,832 Reduced 4.48%	124,221 $213,000
Q2 2023 Aug 08, 2023	BUY	$1.66 - $3.03 $215,887 - $394,060	130,053 New	130,053 $253,000
Q2 2022 Aug 11, 2022	SELL	$1.77 - $4.34 $100,651 - $246,794	-56,865 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.03 - $12.19 $4,715 - $14,262	1,170 Added 2.1%	56,865 $234,000
Q4 2021 Feb 10, 2022	BUY	$8.76 - $13.71 $31,238 - $48,889	3,566 Added 6.84%	55,695 $716,000
Q3 2021 Nov 12, 2021	BUY	$6.41 - $13.54 $12,179 - $25,726	1,900 Added 3.78%	52,129 $563,000
Q2 2021 Aug 05, 2021	BUY	$8.13 - $10.2 $112,494 - $141,137	13,837 Added 38.02%	50,229 $459,000
Q1 2021 May 06, 2021	SELL	$4.07 - $27.11 $8,547 - $56,931	-2,100 Reduced 5.46%	36,392 $343,000
Q4 2020 Feb 10, 2021	BUY	$2.57 - $4.22 $18,175 - $29,843	7,072 Added 22.51%	38,492 $152,000
Q3 2020 Nov 12, 2020	SELL	$2.63 - $8.09 $14,191 - $43,653	-5,396 Reduced 14.66%	31,420 $83,000
Q2 2020 Aug 13, 2020	BUY	$5.69 - $8.17 $37,343 - $53,619	6,563 Added 21.69%	36,816 $244,000
Q1 2020 May 06, 2020	BUY	$5.47 - $11.3 $10,666 - $22,035	1,950 Added 6.89%	30,253 $176,000
Q4 2019 Feb 05, 2020	BUY	$7.07 - $11.61 $1,767 - $2,902	250 Added 0.89%	28,303 $254,000
Q3 2019 Oct 23, 2019	BUY	$8.45 - $12.28 $23,440 - $34,064	2,774 Added 10.97%	28,053 $242,000
Q2 2019 Aug 14, 2019	BUY	$9.2 - $15.7 $232,566 - $396,880	25,279 New	25,279 $282,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account